TNF Pharmaceuticals Files 8-K: Director Changes & More
Ticker: QCLS · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, financials
TL;DR
TNF Pharma 8-K: Director out, new director in, compensation changes, shareholder votes, and financials filed Nov 25.
AI Summary
On November 25, 2024, TNF Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of a new director, and changes in officer compensation arrangements. Additionally, the filing covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate governance updates and potential strategic shifts within TNF Pharmaceuticals, which could impact its future direction and investor relations.
Risk Assessment
Risk Level: medium — Changes in directorship and officer compensation can signal internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- November 25, 2024 (date) — Date of earliest event reported
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- Akers Biosciences, Inc. (company) — Former company name
FAQ
Who departed from the board of directors at TNF Pharmaceuticals?
The 8-K filing indicates the departure of a director, though the specific name is not provided in the initial summary.
Were there any new appointments to the board or officer positions?
Yes, the filing mentions the election of a new director and the appointment of certain officers.
What is the date of the earliest event reported in this 8-K?
The earliest event reported is dated November 25, 2024.
What are the main items covered in this 8-K filing?
The filing covers the departure of directors/officers, election of directors, officer compensation, submission of matters to a vote of security holders, and financial statements/exhibits.
What was TNF Pharmaceuticals, Inc. previously known as?
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and also previously as Akers Biosciences, Inc.
Filing Stats: 1,312 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2024-11-26 08:05:36
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TNFA The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 64KB
- ex10-1.htm (EX-10.1) — 15KB
- 0001493152-24-047742.txt ( ) — 259KB
- tnfa-20241125.xsd (EX-101.SCH) — 3KB
- tnfa-20241125_lab.xml (EX-101.LAB) — 33KB
- tnfa-20241125_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 First Amendment to the TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TNF PHARMACEUTICALS, INC. Date: November 26, 2024 By: /s/ Joshua Silverman Joshua Silverman Director